trending Market Intelligence /marketintelligence/en/news-insights/trending/yuwjq1z-rnujgxekdsfaua2 content esgSubNav
In This List

US appeals court denies Hikma unit's rehearing request in Vanda patent suit

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


US appeals court denies Hikma unit's rehearing request in Vanda patent suit

The U.S. Court of Appeals for the Federal Circuit denied West-Ward Pharmaceutical Corp.'s petitions challenging the outcome of a patent infringement suit.

The subsidiary of London-based Hikma Pharmaceuticals PLC was seeking a rehearing on the court's earlier decision to uphold the U.S. District Court for the District of Delaware's ruling that said it had infringed on U.S. patent number 8,586,610 covering Vanda Pharmaceuticals Inc.'s schizophrenia drug Fanapt.

Washington, D.C.-based Vanda said the patent will expire Nov. 2, 2027.